This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Valneva SE

Drug Names(s): IC47

Description: IC47 is a recombinant subunit vaccine consisting of three conservedsurface proteins from Streptococcus pneumoniae. Two of these proteins were discovered usingIntercell's proprietary Antigen Identification Program (AIP), while the third was in-licensedfrom the U.S. Centers of Disease Control and Prevention (CDC).

Deal Structure: In September 2006, Intercell entered into a partnership with PATH to advance the development of a vaccine against pneumonia in low-income countries. PATH will provide US$7.3 million and work with Intercell on the development of the vaccine.

In May 2013, Valneva announced its creation through the completion of the merger of equals between Vivalis and Intercell.

IC47 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug